EGFR and non-small cell lung carcinoma: This agent was evaluated in phase III studies in two different settings: initially, in second-line T790M mutation-positive NSCLC post progression on prior EGFR TKI treatment (AURA3), and subsequently in the first-line setting irrespective of T790M mutation status (FLAURA) [40,41].